- Home
- CEPV vs KMDA Comparison
CEPV vs KMDA Comparison
Compare CEPV & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPV | KMDA |
|---|---|---|
| Founded | 2021 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.5M | 385.3M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | CEPV | KMDA |
|---|---|---|
| Price | $10.23 | $7.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 37.5K | ★ 101.0K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | N/A | ★ 30.41 |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | ★ $174,787,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $10.74 |
| P/E Ratio | ★ N/A | $20.05 |
| Revenue Growth | N/A | ★ 10.36 |
| 52 Week Low | $10.20 | $5.54 |
| 52 Week High | $10.36 | $9.16 |
Technical Indicators
Market Signals| Indicator | CEPV | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.82 |
| Support Level | N/A | $6.97 |
| Resistance Level | N/A | $7.45 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 56.24 |
Price Performance
Historical ComparisonAbout CEPV Cantor Equity Partners V Inc. Class A Ordinary Shares
Cantor Equity Partners V Inc is a blank check company.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.